Liver mass diagnostic study of choice: Difference between revisions
m (Bot: Removing from Primary care) |
|||
(3 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Liver mass}} | {{Liver mass}} | ||
{{CMG}}{{AE}}{{MV}} | {{CMG}}; {{AE}}{{MV}} | ||
==Overview== | ==Overview== | ||
[[Liver biopsy]] is the gold standard test for the diagnosis of liver mass. Common indications for biopsy in liver mass includes suspected [[hepatocellular carcinoma]], and unspecific imaging findings. The most important contraindication for [[biopsy]] in liver mass is suspected liver [[hemangioma]]. | |||
Liver | |||
==Biopsy== | ==Biopsy== | ||
Line 19: | Line 18: | ||
* [[Laparoscopic surgery|Laparoscopic]] [[liver biopsy]] | * [[Laparoscopic surgery|Laparoscopic]] [[liver biopsy]] | ||
* Transjugular [[liver biopsy]] | * Transjugular [[liver biopsy]] | ||
{| | {| | ||
! | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Findings on Biopsy | |||
|- | |- | ||
|Focal nodular hyperplasia | ! align="center" style="background:#DCDCDC;" + |Focal nodular hyperplasia | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
* Fibrous septa between hepatocytes which form a stellate scar | * Fibrous septa between [[hepatocytes]] which form a stellate scar | ||
* Chronic cholestasis | * Chronic [[cholestasis]] | ||
* Prominent arteries | * Prominent arteries | ||
|- | |- | ||
|Hepatocellular carcinoma | ! align="center" style="background:#DCDCDC;" + |Hepatocellular carcinoma | ||
|Two out of the following three positive stains upon liver biopsy confirm HCC:<ref name="pmid19177576">{{cite journal |vauthors= |title=Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia |journal=Hepatology |volume=49 |issue=2 |pages=658–64 |year=2009 |pmid=19177576 |doi=10.1002/hep.22709 |url=}}</ref><ref name="pmid20400233">{{cite journal |vauthors=Karabork A, Kaygusuz G, Ekinci C |title=The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma |journal=Pathol. Res. Pract. |volume=206 |issue=8 |pages=572–7 |year=2010 |pmid=20400233 |doi=10.1016/j.prp.2010.03.004 |url=}}</ref> | | align="left" style="background:#F5F5F5;" + |Two out of the following three positive stains upon liver biopsy confirm HCC:<ref name="pmid19177576">{{cite journal |vauthors= |title=Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia |journal=Hepatology |volume=49 |issue=2 |pages=658–64 |year=2009 |pmid=19177576 |doi=10.1002/hep.22709 |url=}}</ref><ref name="pmid20400233">{{cite journal |vauthors=Karabork A, Kaygusuz G, Ekinci C |title=The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma |journal=Pathol. Res. Pract. |volume=206 |issue=8 |pages=572–7 |year=2010 |pmid=20400233 |doi=10.1016/j.prp.2010.03.004 |url=}}</ref> | ||
*[[Glypican 3]] | *[[Glypican 3]] | ||
*[[Heat shock protein 70 (Hsp70) internal ribosome entry site (IRES)|Heat shock protein 70]] | *[[Heat shock protein 70 (Hsp70) internal ribosome entry site (IRES)|Heat shock protein 70]] | ||
*[[Glutamine synthetase]] | *[[Glutamine synthetase]] | ||
|- | |- | ||
|Cirrhosis | ! align="center" style="background:#DCDCDC;" + |Cirrhosis | ||
| | | align="left" style="background:#F5F5F5;" + | | ||
* Bridging fibrous septa | * Bridging fibrous septa | ||
* Parenchymal [[Nodule (medicine)|nodules]] bearing a mixture of replicating and senescent [[Hepatocyte|hepatocytes]] | |||
* Parenchymal [[Nodule (medicine)|nodules]] bearing a mixture of replicating and | |||
|} | |} | ||
Line 53: | Line 51: | ||
*[[Bleeding]] | *[[Bleeding]] | ||
*Seeding of neoplastic cells<br> | *Seeding of neoplastic cells<br> | ||
==References== | ==References== | ||
{{ | {{Reflist|2}} | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Gastroenterology]] | |||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category: | [[Category:Oncology]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Surgery]] | [[Category:Surgery]] |
Latest revision as of 22:31, 29 July 2020
Liver Mass Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Liver mass diagnostic study of choice On the Web |
American Roentgen Ray Society Images of Liver mass diagnostic study of choice |
Risk calculators and risk factors for Liver mass diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
Liver biopsy is the gold standard test for the diagnosis of liver mass. Common indications for biopsy in liver mass includes suspected hepatocellular carcinoma, and unspecific imaging findings. The most important contraindication for biopsy in liver mass is suspected liver hemangioma.
Biopsy
Biopsy is always indicated in patients presenting with liver mass to rule out malignancy. Biopsy findings associated with liver mass will depend on tumor histology. [1]
Indications
Indications for biopsy in liver mass, include:
- Suspected hepatocellular carcinoma[1]
- Unspecific and inconclusive liver mass imaging findings
Types
- Percutaneous, ultrasound-guided liver biopsy
- Laparoscopic liver biopsy
- Transjugular liver biopsy
Disease | Findings on Biopsy |
---|---|
Focal nodular hyperplasia |
|
Hepatocellular carcinoma | Two out of the following three positive stains upon liver biopsy confirm HCC:[2][3] |
Cirrhosis |
|
Contraindications
- Contraindications for biopsy in liver mass, include:[1]
- Suspected hemangioma
- Adenomas
- Patients on of anticoagulant therapy
- Unstable medical conditions (e.g. acute heart failure)
Complications
Complications for for biopsy in liver mass, include:[1]
- Bleeding
- Seeding of neoplastic cells
References
- ↑ 1.0 1.1 1.2 1.3 Borzio M, Borzio F, Macchi R, Croce AM, Bruno S, Ferrari A, Servida E (1994). "The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis". J. Hepatol. 20 (1): 117–21. PMID 8201212.
- ↑ "Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia". Hepatology. 49 (2): 658–64. 2009. doi:10.1002/hep.22709. PMID 19177576.
- ↑ Karabork A, Kaygusuz G, Ekinci C (2010). "The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma". Pathol. Res. Pract. 206 (8): 572–7. doi:10.1016/j.prp.2010.03.004. PMID 20400233.